Showing 1641-1650 of 2050 results for "".
- EyePoint Begins Phase 2 VERONA Clinical Trial of EYP-1901 to Treat Diabetic Macular Edemahttps://modernod.com/news/eyepoint-begins-phase-2-verona-clinical-trial-of-eyp-1901-to-treat-diabetic-macular-edema/2482049/EyePoint Pharmaceuticals, a company focused on therapeutics for retinal diseases, announced that the first patient has been dosed in the VERONA clinical trial of the company’s EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vor
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Belkin Vision Announces FDA Clearance for the Eagle for Selective Laser Trabeculoplastyhttps://modernod.com/news/belkin-vision-announces-fda-clearance-for-the-eagle-device/2482005/Belkin Vision has received FDA 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser intended for use in performing selective laser trabeculoplasty (SLT). Belkin describes the Eagle as the first and only contactless l
- Ocutrx Unveils OcuLenz AR/XR Headset, Aiding Vision for Patients with Advanced Macular Degenerationhttps://modernod.com/news/ocutrx-unveils-oculenz-arxr-headset-aiding-vision-for-patients-with-advanced-macular-degeneration/2481968/Ocutrx Technologies has released the OcuLenz AR/XR headset, which is designed to enhance visual clarity for people living with advanced age-related macular degeneration (AMD). The AR/XR headset enhances vision by overlaying high-contrast, pixel-manipulated images onto the user
- GATHER2 Study Shows Izervay Monthly or Every Other Month Reduced GA Lesion Growth Through 2 Yearshttps://modernod.com/news/gather2-study-shows-izervay-monthly-or-every-other-month-reduced-ga-lesion-growth-through-2-years/2481944/Astellas Pharma announced results from the GATHER2 phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy (GA) lesion growth for both every month (EM) and every-other-month (EOM) dosing vs. sham through
- Ace Vision Group Adds Four Ophthalmologists to Medical Advisory Board; Launches New Corporate and Medical Affairs Websiteshttps://modernod.com/news/ace-vision-group-adds-four-ophthalmologists-to-medical-advisory-board-launches-new-corporate-and-medical-affairs-websites/2481941/Ace Vision Group announced the addition of Cathleen McCabe, MD; James Katz, MD; Ehsan Sadri, MD; and Dagny Zhu, MD, to its medical advisory board. These prominent ophthalmologists will contribute expertise to advance the development and implementation of novel solutions for e
- Sight Sciences Presents Phase 1 Results of the SAHARA Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/sight-sciences-presents-phase-1-results-of-the-sahara-trial-comparing-tearcare-to-restasis-for-the-treatment-of-dry-eye-disease/2481888/Sight Sciences announced the presentation of the full phase 1 results from the SAHARA randomized controlled trial, demonstrating that interventional eyelid procedures for dry eye disease enabled by TearCare technology were superior at all measured time points to Restasis prescription eye dro
- Alcon Showcases New TOTAL30 Multifocal Lenses and Other Innovations at #Academy23https://modernod.com/news/alcon-demonstrates-commitment-to-innovation-at-academy23-showcasing-total30-multifocal/2481884/Alcon will introduce TOTAL30 Multifocal, the first and only reusable Water Gradient multifocal contact lens, along with the latest advancements in eye care technology at the American Academy of Optometry Annual Meeting (#Academy23) in New Orleans, October 11-14, 2023. Alcon&rs
- Dopavision Completes Enrollment for MyopiaX-1 Trialhttps://modernod.com/news/dopavision-completes-enrollment-for-myopiax-1-trial/2481847/Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the saf
- Bausch + Lomb Launches Lumify Eye Illuminations in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-eye-illuminations-in-the-united-states/2481846/Bausch + Lomb announced the US launch of Lumify Eye Illuminations, a new line of hypoallergenic specialty eye care products developed to cleanse, nourish and brighten the sensitive eye area. “Many products contain chemicals or preservatives that can irritate the del